Walker JL, et al. - Among women with newly diagnosed advanced ovarian carcinoma, researchers assessed the influence of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS). A total of 1,560 participants were registered and followed up for 84.8 months. Data reported that the median PFS duration was 24.9 months in the intravenous carboplatin arm, 27.4 months in the IP carboplatin arm, and 26.2 months in the IP cisplatin arm. Investigators found that the duration of PFS was not significantly increased with either IP regimen in combination with bevacizumab compared to the IV carboplatin reference arm and was better tolerated than IP cisplatin.